- Home
- TARS vs VCEL Comparison
TARS vs VCEL Comparison
Compare TARS & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | VCEL |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TARS | VCEL |
|---|---|---|
| Price | $69.20 | $44.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $89.00 | $57.75 |
| AVG Volume (30 Days) | ★ 831.4K | 460.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.21 | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | $276,259,000.00 |
| Revenue This Year | $56.43 | $19.40 |
| Revenue Next Year | $30.19 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 146.71 | 16.45 |
| 52 Week Low | $48.20 | $28.95 |
| 52 Week High | $85.25 | $49.32 |
Technical Indicators
Market Signals| Indicator | TARS | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 46.04 |
| Support Level | $60.95 | $32.44 |
| Resistance Level | $73.45 | $49.04 |
| Average True Range (ATR) | 3.30 | 1.56 |
| MACD | 1.12 | -0.39 |
| Stochastic Oscillator | 84.67 | 16.94 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.